Previous 10 | Next 10 |
Zynex Ranked in Top 50 Public Companies in Colorado PR Newswire ENGLEWOOD, Colo. , Aug. 3, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devi...
Zynex beat analysts' estimates despite the recession. Zynex is committed to bringing value to its shareholders with a new share buyback round. The company reaffirmed the guidance without considering the sale of CM-1600. Quarterly results in pills Zynex, Inc. ( ZYXI...
Two new Breakout Stocks for Week 31 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns declined to +90.9% YTD. This week, one pick FXLV wiped out the weekly portfolio gains with their CEO termination and lowered revenue guidance ahead of Aug...
Zynex ( NASDAQ: ZYXI ) stock rose ~12% on July 29 after Q2 results beat analysts' estimates and the company reaffirmed its FY22 revenue outlook a day ago. The Englewood, Colo.-based medical device maker's Q2 revenue grew +18.49% Y/Y to $36.76M. "Our reps...
Zynex, Inc. (ZYXI) Q2 2022 Results Conference Call July 28, 2022 04:15 PM ET Company Participants Louisa Smith - Investor Relations-Gilmartin Group Thomas Sandgaard - Chairman, President and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna ...
Zynex press release ( NASDAQ: ZYXI ): Q2 GAAP EPS of $0.08 beats by $0.01 . Revenue of $36.76M (+18.6% Y/Y) beats by $0.46M . Zynex is reaffirming its full year 2022 revenue estimates in the range of $150-$170 million and Adjusted EBITDA between $25-$35 million...
Zynex Announces 2022 Second Quarter Earnings PR Newswire ENGLEWOOD, Colo. , July 28, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
Zynex ( NASDAQ: ZYXI ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is $0.07 and the consensus Revenue Estimate is $36.3M (+17.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward rev...
AAPL , AEMD , AJG , ALEX , AMZN , APPF , ATR , AUY , AVTR , AXTI , BIO , OTCPK:BTEGF , BZH , CC , CE , CLFD , CLR , COHU , CPT , CTO , CUZ , CWST , DECK , DLR , DXCM , EB , EBC , ...
Zynex continues to grow its top-line sequentially, set to post another record quarter in Q2. Despite this, investors have punished the stock in FY22, in search of idiosyncratic risk premia over beta-related return. In that vein, we find a lack of equity premia in ZYXI that investo...
News, Short Squeeze, Breakout and More Instantly...
Zynex Sets Second Quarter 2024 Earnings Call PR Newswire ENGLEWOOD, Colo. , July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain manage...
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces PR Newswire ENGLEWOOD, Colo. , July 11, 2024 /PRNewswire/ -- Zy...